Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic vinorelbine plus tislelizumab in EGFR/ALK‑negative advanced NSCLC intolerant to first‑line standard chemotherapy
ChiCTR2200061304Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: progression-free survival. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
vinorelbinetislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200061304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061304.